Therapeutic agent for drug-resistant hypercalcemia

摘要

1. the use of substances that can inhibit the u0441u0432u00a0u0437u044bu0432u0430u043du0438u0435 protein, software u043fu0430u0440u0430u0442u0438u0440u0435u043eu0438u0434u043du043eu043cu0443 u0433u043eu0440u043cu043eu043du0443 (PTHrP) with his u0440u0435u0446u0435u043fu0442u043eu0440u043eu043c, u0434u043bu00a0 u043fu043eu043bu0443u0447u0435u043du0438u00a0 therapeutic u0441u0440u0435u0434u0441 twa u0434u043bu00a0 u043bu0435u0447u0435u043du0438u00a0 resistant to drugs u0433u0438u043fu0435u0440u043au0430u043bu044cu0446u0438u0435u043cu0438u0438.;2. application of 1, where u0443u0441u0442u043eu0439u0447u0438u0432u0430u00a0 medicines u0433u0438u043fu0435u0440u043au0430u043bu044cu0446u0438u0435u043cu0438u00a0 u00a0u0432u043bu00a0u0435u0442u0441u00a0 resistant to therapeutic agent intended u0434u043bu00a0 u043bu0435u0447u0435u043du0438u00a0 u0433u0438u043fu0435u0440u043au0430 u043bu044cu0446u0438u0435u043cu0438u0438, distinct from the substance which can inhibit the u0441u0432u00a0u0437u044bu0432u0430u043du0438u0435 protein, software u043fu0430u0440u0430u0442u0438u0440u0435u043eu0438u0434u043du043eu043cu0443 u0433u043eu0440u043cu043eu043du0443 (PTHrP) with his u0440u0435u0446u0435u043fu0442u043eu0440u043eu043c.;3. application of 1, where the therapeutic agent u0434u043bu00a0 u043bu0435u0447u0435u043du0438u00a0 u0433u0438u043fu0435u0440u043au0430u043bu044cu0446u0438u0435u043cu0438u0438 u043fu0440u0435u0434u0441u0442u0430u0432u043bu00a0u0435u0442 an agent, u0438u043du0433u0438u0431u0438u0440u0443u044eu0449u0438u0439 bone resorption, agent to u044du043au0441u043au0440u0435u0446u0438 and u043au0430u043bu044cu0446u0438u00a0, agent, u0438u043du0433u0438u0431u0438u0440u0443u044eu0449u0438u0439 removals u043au0430u043bu044cu0446u0438u00a0 in intestinal tract, or u043fu0435u0442u0435u043bu044cu043du044bu0439 u0434u0438u0443u0440u0435u0442u0438u043a.;4. application 2, where the therapeutic agent u0434u043bu00a0 u043bu0435u0447u0435u043du0438u00a0 u0433u0438u043fu0435u0440u043au0430u043bu044cu0446u0438u0435u043cu0438u0438 u043fu0440u0435u0434u0441u0442u0430u0432u043bu00a0u0435u0442 an agent, u0438u043du0433u0438u0431u0438u0440u0443u044eu0449u0438u0439 bone resorption.;5. application of paragraph 4, where an agent u0438u043du0433u0438u0431u0438u0440u0443u044eu0449u0438u0439 bone resorption, u043fu0440u0435u0434u0441u0442u0430u0432u043bu00a0u0435u0442 a u0431u0438u0441u0444u043eu0441u0444u043eu043du0430u0442 or u043au0430u043bu044cu0446u0438u0442u043eu043du0438u043d.;6. the use of any of the u043fu043f.1 - 5, where the substance u00a0u0432u043bu00a0u0435u0442u0441u00a0 u0430u043du0442u0430u0433u043eu043du0438u0441u0442u043eu043c u0440u0435u0446u0435u043fu0442u043eu0440u0430 PTHrP.;7. the use of any of the u043fu043f.1 - 5, where the substance u043fu0440u0435u0434u0441u0442u0430u0432u043bu00a0u0435u0442 an antibody against PTHrP.;8. the use of any of the u043fu043f.1 - 5, where the substance u043fu0440u0435u0434u0441u0442u0430u0432u043bu00a0u0435u0442 a fragment of the antibody against PTHrP and / or a modified form of the fragment.;9. application on p.7, where u00a0u0432u043bu00a0u0435u0442u0441u00a0 u043cu043eu043du043eu043au043bu043eu043du0430u043bu044cu043du044bu043c antibody.;10. application on p.7, where an antibody u00a0u0432u043bu00a0u0435u0442u0441u00a0 human u0433u0443u043cu0430u043du0438u0437u0438u0440u043eu0432u0430u043du043du044bu043c or u0445u0438u043cu0435u0440u043du044bu043c u0430u043du0442u0438u0442u0435u043bu043eu043c.;11. application on p.7, where the antibody is provided in the form of soft.;12. application of the p.11, where u0433u0443u043cu0430u043du0438u0437u0438u0440u043eu0432u0430u043du043du043eu0435 antibody u043fu0440u0435u0434u0441u0442u0430u0432u043bu00a0u0435u0442 a u0433u0443u043cu0430u043du0438u0437u0438u0440u043eu0432u0430u043du043du043eu0435 antibody # 23 - 57 - 137 - 1.;13. application of 1, where u0443u0441u0442u043eu0439u0447u0438u0432u0430u00a0 medicines u0433u0438u043fu0435u0440u043au0430u043bu044cu0446u0438u0435u043cu0438u00a0 caused by cancer.